Accuracy of measured vancomycin serum concentrations in patients with end-stage renal disease

Annals of Pharmacotherapy

Volumn 33, Issue 12, 1999, Pages 1329-1335

  Smith, Patrick F ^a   Morse, Gene D ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Assays; Concentrations; End stage renal disease; Vancomycin

Indexed keywords

VANCOMYCIN; VANCOMYCIN DERIVATIVE;

ACCURACY; CONTROLLED STUDY; CROSS REACTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; DRUG STRUCTURE; IMMUNOASSAY; KIDNEY FAILURE; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

EID: 0033385252     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19130     Document Type: Review

References (36)

1. Pollard TA, Lampasona V, Akkerman S, Tom K, Hooks MA, Mullins RE, et al. Vancomycin redistribution: dosing recommendations following high-flux hemodialysis. Kidney Int 1994;45:232-7.
2. Follin SL, Mueller BA, Scott MS. Falsely elevated serum vancomycin concentrations in hemodialysis patients. Am J Kidney Dis 1996;1:67-74.
3. Morse GD, Nairn DK, Bertino JS, Walshe JJ. Overestimation of vancomycin concentrations utilizing fluorescence polarization immunoassay in patients on peritoneal dialysis. Ther Drug Monit 1987;2:212-5.
4. Najjar TA, al-Dhuwailie AA, Tekle A. Comparison of high-performance liquid chromatography with fluorescence polarization immunoassay for the analysis of vancomycin in patients with chronic renal failure. J Chromatogr B Biomed Appl 1995;672:295-9.
5. Kim JS, Perkins RJ, Briceland LL, Tobin EH. Clinical significance of falsely elevated vancomycin concentrations in end-stage renal disease (letter). Ann Pharmacother 1999;33:116-8.
6. Marshall FJ. Structure studies on vancomycin. J Med Chem 1965;8:18-22.
7. Harris CM, Kopecka H, Harris TM. Vancomycin: structure and transformation to CDP-1. J Am Chem Soc 1983;105:6915-22.
8. Anne L, Hu M, Chan K, Colin L, Gottwald K. Potential problem with fluorescence polarization immunoassay cross-reactivity to vancomycin degradation product CDP-1: its detection in sera of renally impaired patients. Ther Drug Monit 1989;11:585-91.
9. White LO, Edwards R, Holt HA, Lovering A, Finch RG, Reeves DS. The in-vitro degradation at 37 °C of vancomycin in serum, CAPD fluid and phosphate-buffered saline. J Antimicrob Chemother 1988;22:739-45.
10. Buffone GJ. Principles of immunochemical methods. In: Tietz NW, ed. Fundamentals of clinical chemistry. 3rd ed. Philadelphia: WB Saunders Co., 1987:144-57.
11. Yeo KT, Traverse W, Horowitz GL. Clinical performance of the EMIT vancomycin assay. Clin Chem 1989;35:1504-7.
12. Saunders NJ, Want SV, Adams DJ. Assay of vancomycin by fluorescence polarisation immunoassay and EMIT in patients with renal failure. J Antimicrob Chemother 1995;36:2411-5.
13. Perino LM, Mueller BA. Accuracy of vancomycin serum concentrations in patients with renal failure. Ann Pharmacother 1993;27:892-3.
14. Morishige H, Shuto H, Ieiri I, Otsubo K, Oishi R. Instability of standard calibrators may be involved in overestimating vancomycin concentrations determined by fluorescence polarization immunoassay. Ther Drug Monit 1996;18:80-5.
15. Jolley ME, Stroupe SD, Schwenzer KS. Fluorescence polarization immunoassay III: an automated system for therapeutic drug determination. Clin Chem 1981;27:1575-9.
16. Tiffany TO, Burtis CA. Fluorometry, nephelometry, and turbidimetry. In: Tietz NW, ed. Fundamentals of clinical chemistry. 3rd ed. Philadelphia: WB Saunders Co., 1987:66-73.
17. Hortin GL, Landt M, Wilhite T, Smith CH. Cross-reactivity of a vancomycin degradation product in three immunoassays of vancomycin (letter). Clin Chem 1991;37:2009.
18. 12 internal standard: comparison of HPLC, EMIT, and FPIA methods. Ther Drug Monit 1990;6:562-9.
19. Moellering RO, Krogstad DJ, Greenblatt DJ. Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981;94:343-6.
20. Peckman HJ, Dupuis RE, Sawyer WT, Brouwer KLR, Cross RE. Vancomycin serum concentrations in patients with renal dysfunction: a comparison of fluorescence polarization immunoassay and the enzyme-multiplied immunoassay technique. Ther Drug Monit 1996;18:647-53.
21. Schaad UB, McCracken GH, Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 1980;96:119-26.
22. Zimmerman Z, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy 1995;1:85-91.
23. Adamczyk M, Brate EM, Chiappetta EG, Ginsburg S, Hoffman E, Klein C, et al. Development of a quantitative vancomycin immunoassay for the Abbott AxSYM analyzer. Ther Drug Monit 1998;20:191-201.
24. Azzazy HM, Chou PP, Tsushima JH, Troxil S, Gordon M, Avers RJ, et al. Abbott AxSYM Vancomycin II assay: multicenter evaluation and interference studies. Ther Drug Monit 1998;20:202-8.
25. Smith PF, Petros WP, Soucie MP, Copeland KR. New modified fluorescence polarization immunoassay does not falsely elevate vancomycin concentrations in patients with end-stage renal disease. Ther Drug Monit 1998;20:231-5.
26. Aldwin L, Kabakoff DS. Metabolite interference in homogeneous enzyme immunoassay of phenytoin (letter). Clin Chem 1981;27:770-1.
27. Matzke GR, Sawchuk RJ. Elevated serum phenytoin concentrations in a uremic patient when measured by enzyme-multiplied immunoassay. Drug Intell Clin Pharm 1981;15:386-8.
28. Sawchuk RJ, Matzke GR. Contribution of 5-(4-hydroxy-phenyl)-5-phenyl-hydantoin to the discrepancy between phenytoin analysis by EMIT and high-pressure liquid chromatography. Ther Drug Monit 1984; 6:97-103.
29. Opheim KE, Ainardi V. Increase in apparent theophylline concentration in the serum of two uremic patients as measured by some immunoassay methods (caused by 1,3-dimethyluric acid) (letter). Clin Chem 1983;29: 1698-9.
30. Bridges RR, Jennison TA. Spurious phenobarbital levels by fluorescence polarization immunoassay using TDx analyzer in patients with renal disease. Ther Drug Monit 1984;6:368-70.
31. Aherne GW, Littleton P. Morphine-6-glucuronide, an important factor in interpreting morphine radioimmunoassays. Lancet 1985;2:210-1.
32. Compton R, Lichti D. Influence of uremia on four assays for theophylline: improved results with a monoclonal antibody in the TDx procedure. Clin Chem 1985;31:152-4.
33. Raisys VA, Opheim KE, Thorson CS, Ainardi V. Determination of serum phenytoin in uremic and non-uremic patients using EMIT monoclonal assay (abstract). Clin Chem 1985;31:931.
34. Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother 1993;27:594-8.
35. Leader WG, Chandler MHH, Castiglia M. Pharmacokinetic optimisation of vancomycin therapy. Clin Pharmacokinet 1995;28:327-42.
36. Pryka RD. Vancomycin serum concentration monitoring: a continued debate. Ann Pharmacother 1994;28:1397-9.